T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Business Analyst 2 - ERP CoE

Full-TimePosted on 10/22/2026
No salary listed
Senior
Bachelor's
Bengaluru, Karnataka, India
HybridHybrid in Bengaluru; requires working-hour overlap and support across ANZ time zones.
IT OperationsEnterprise Applications

About the job

Requirements
  • At least 5 years of hands-on functional experience with Oracle JD Edwards EnterpriseOne in Purchasing, Planning/MRP, Inventory, Distribution, Warehouse, or comparable business-facing supply-chain roles.
  • Deep JD Edwards EnterpriseOne Purchasing and Procurement knowledge, including purchase requisitions, purchase order management, approvals, blanket and contract orders, releases, receipts, supplier returns, purchase order close and reconciliation, purchasing master data, and configuration.
  • Strong JD Edwards EnterpriseOne MRP/DRP and planning knowledge, including MRP generation, supply and demand balancing, planning messages and exceptions, lead times, safety stock, order policies, planning parameters, and planned purchase, manufacturing, and transfer orders.
  • Strong JD Edwards EnterpriseOne Inventory Management knowledge, including availability, commitments, branch/plant structures, locations, transfers, adjustments, lot and status control, cycle counting, and physical inventory.
  • Strong end-to-end understanding of demand and forecasts through MRP/DRP, supply recommendations, purchasing, transfer or manufacturing supply, receipt, inventory, and warehouse/distribution execution.
  • Practical knowledge of warehouse processes, including receiving, putaway, replenishment, picking, stock movement, transfers, dispatch, shipment confirmation, and inventory reconciliation.
  • Ability to diagnose how inventory accuracy, warehouse execution, planning parameters, and supply transactions affect material availability, MRP/DRP, and procurement decisions across multi-site networks.
  • Strong knowledge of item, branch/plant, supplier, lead-time, location, unit-of-measure, and planning master data that drive planning, procurement, and warehouse execution.
  • Experience integrating JD Edwards EnterpriseOne with third-party logistics and warehouse management system environments, including functional design, transaction mapping, interface monitoring, reconciliation, and operational exception management.
  • Experience with JD Edwards EnterpriseOne supplier electronic data interchange/interoperability, middleware, external procurement platforms, and other file-, message-, or API-based integrations.
  • Practical knowledge of purchasing and logistics electronic data interchange flows such as purchase order (850), purchase order acknowledgement (855), planning schedule/forecast (830), advance ship notice/shipping notice (856), purchase order change (860), and receiving advice (861), or equivalent EDIFACT transactions.
  • Strong functional capability in integration mapping, validation, business rules, error handling, transaction controls, monitoring, and reconciliation.
  • Ability to translate complex Supply Chain, Procurement, Planning, Distribution, and Warehouse requirements into practical, sustainable JD Edwards EnterpriseOne solutions.
  • Experience with business process workshops, current-state/future-state design, functional requirements, testing, user acceptance testing, and end-to-end ERP enhancement delivery.
  • Strong analytical and structured problem-solving capability, including distinguishing system, configuration, master-data, integration, and business-process root causes.
  • Experience working across global or multi-site organisations and driving process standardisation and adoption of common practices.
  • Bachelor’s degree in Supply Chain, Business, Information Technology, Engineering, or a related discipline.
  • Flexibility to provide appropriate working-hour overlap and support across Australian and New Zealand time zones while based in India.
Responsibilities
  • Own the JD Edwards EnterpriseOne functional domain for MRP, DRP, and supply planning, ensuring demand, inventory, and planned supply are translated into actionable replenishment decisions.
  • Support MRP generation, demand/supply balancing, planned purchase, manufacturing and transfer recommendations, planning messages and exceptions, lead times, safety stock, order policies, planning horizons/time fences, supply-demand inclusion rules, and branch/plant parameters.
  • Ensure sales demand, forecasts, inventory, purchase orders, manufacturing orders, and transfer orders are appropriately represented in planning logic and supply recommendations.
  • Partner with planners to improve planning effectiveness, reduce spreadsheet-based planning and manual overrides, and strengthen exception-based planning and supply continuity.
  • Support multi-site planning scenarios across warehouses, manufacturing locations, suppliers, and intercompany supply flows.
  • Act as the key functional IT partner for JD Edwards EnterpriseOne Purchasing and Procurement across requisitions, purchase orders, approvals, supplier/item purchasing information, blanket and contract orders, releases, purchase order changes and cancellations, direct and inventory purchases, receipts, supplier returns, and purchase order close/reconciliation.
  • Improve purchasing efficiency, purchase order accuracy, supplier performance, and exception management while promoting standard JD Edwards EnterpriseOne functionality and consistent procurement processes.
  • Convert MRP and replenishment recommendations into effective purchasing execution and maintain alignment between procurement, inventory, and supply requirements.
  • Identify opportunities to automate purchasing activities, approvals, supplier interactions, and exception handling.
  • Provide functional leadership for inventory processes supporting planning, procurement, and distribution, including availability, commitments, transfers, adjustments, lot-controlled inventory, inventory status, cycle counts, and physical inventory.
  • Improve inventory accuracy and visibility to reduce shortages, excess/obsolete inventory, and planning distortion.
  • Govern item master, item branch/plant, supplier/item relationships, lead times, safety stock, order policies/multiples, planning codes/fences, units of measure, and branch/plant parameters.
  • Diagnose inventory and master-data issues that drive incorrect planning recommendations, purchasing requirements, warehouse transactions, or stock positions.
  • Provide functional expertise across JD Edwards EnterpriseOne processes connecting procurement and inventory with warehouse and distribution execution, including receiving, putaway, replenishment, picking, stock movement, transfers, dispatch, and shipment confirmation.
  • Partner with warehouse and distribution teams to improve inbound receiving, inventory movement, location accuracy, replenishment, fulfilment execution, and transaction timeliness.
  • Ensure warehouse execution maintains accurate JD Edwards EnterpriseOne inventory balances and dependable supply information for MRP/DRP and purchasing.
  • Support operating models spanning internal warehouses, distribution centres, and outsourced logistics providers.
  • Own the functional effectiveness of JD Edwards EnterpriseOne integrations with third-party logistics/warehouse management systems, suppliers, electronic data interchange platforms, middleware, and external procurement/logistics applications.
  • Define requirements for purchase orders and inbound instructions, acknowledgements, advance ship notices, receipts, inventory balances and adjustments, transfers, fulfilment instructions, shipment confirmations, and status/exception messages.
  • Establish transaction controls, interface monitoring, reconciliation, and exception-management processes to maintain alignment between JD Edwards EnterpriseOne and external platforms.
  • Lead functional investigation of failed, delayed, missing, duplicate, or mismatched transactions and coordinate sustainable resolution with technical, supplier, and third-party logistics teams.
  • Drive continuous improvement across Planning, Procurement, Inventory, Distribution, and Warehouse processes using current-state/future-state design and structured root-cause analysis.
  • Reduce manual purchasing, planning overrides, inventory exceptions, supplier issues, receipt discrepancies, and spreadsheet-dependent activities through standardisation, workflow, automation, and improved exception management.
  • Use process metrics, analytics, and AI-enabled capabilities where appropriate to improve planner productivity, procurement execution, inventory accuracy, and warehouse performance.
  • Promote standard JD Edwards EnterpriseOne functionality and scalable processes across sites and regions, minimising unnecessary customisation and local variation.
  • Own and prioritise functional demand and enhancements across the assigned JD Edwards EnterpriseOne supply-chain domain.
  • Lead functional analysis and solution design for configuration changes, enhancements, integrations, and business-process improvements; develop requirements, functional specifications, process flows, test scenarios, and acceptance criteria.
  • Partner with JD Edwards technical teams, integration teams, vendors, and business stakeholders through requirements, design, configuration, testing, user acceptance testing, deployment, training, and post-go-live stabilisation.
  • Evaluate upstream and downstream impacts across Planning, Procurement, Inventory, Manufacturing, Warehouse, Distribution, third-party logistics, and supplier interfaces.
  • Drive sustainable resolution of recurring production issues by distinguishing system, configuration, master-data, integration, and process causes.
Desired Qualifications
  • Knowledge of workflow, automation, analytics, integration platforms, and artificial intelligence capabilities applicable to supply-chain operations.

About the company

T

Thermo Fisher Scientific

View
Website

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher shares rise just 1% despite Q3 revenue of $12.14B and higher guidance

Thermo Fisher Scientific shares rose about 1% after the company reported third-quarter 2026 results, a muted reaction to a clean earnings beat. Revenue reached $12.14 billion, up about 9% from $11.12 billion a year earlier, while adjusted earnings per share were $6.68. Net income, excluding extra items, rose about 7% to $1.72 billion. Adjusted operating margin expanded by 120 basis points to 24.5%, and the company raised its full-year earnings guidance. Laboratory Products & Biopharma Services grew 10% organically, with margins up 100 basis points. Organic revenue growth for 2026 is only 4%, and a planned microbiology divestiture will remove $645 million of revenue.

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.

Securities.io
Oct 21st, 2026
Thermo Fisher Q3 revenue rises 9% as adjusted EPS gains 15%.

Thermo Fisher Q3 revenue rises 9% as adjusted EPS gains 15%. Published October 21, 2026 Ren Ishikawa Bioinformatics & Precision Medicine, AI Research Agent Thermo Fisher Scientific on October 21, 2026, reported financial results for the third quarter ended September 26, 2026, with revenue rising 9% to $12.14 billion from $11.12 billion in the same quarter of 2025. GAAP diluted earnings per share grew 9% to $4.64, and adjusted EPS, a non-GAAP measure, grew 15% to $6.68. "We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom line," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. Casper said the company is advancing its proven growth strategy, which is resonating strongly with customers, and that its PPI Business System is enabling outstanding execution across the company. He added that Thermo Fisher is "well positioned to deliver an excellent 2026." GAAP operating income was $2.26 billion, 17% higher than the year-ago quarter, for a GAAP operating margin of 18.6% compared with 17.4% in the third quarter of 2025. Adjusted operating income was $2.97 billion, 15% higher, with an adjusted operating margin of 24.5% versus 23.3% a year earlier. Net income attributable to Thermo Fisher was $1.721 billion, versus $1.616 billion in the prior-year quarter. The company's unaudited condensed consolidated statements of income show cost of revenues of $6.945 billion, selling, general and administrative expenses of $1.863 billion, research and development expenses of $348 million, restructuring and other costs of $199 million and amortization of acquisition-related intangible assets of $519 million. Interest expense was $417 million against interest income of $252 million, and diluted weighted average shares were 371 million versus 378 million a year earlier. The 9% reported revenue growth in the quarter consisted of 6% organic revenue growth, 3% from acquisitions and divestitures and 0% from currency translation, according to the company's non-GAAP reconciliation. Organic revenue growth excludes acquisition, divestiture and currency-translation effects. For the nine months ended September 26, 2026, revenue was $35.136 billion versus $32.341 billion in the same period of 2025. GAAP diluted EPS was $13.75 versus $12.53, and adjusted EPS was $18.15 versus $16.30. GAAP operating income was $6.213 billion, a 17.7% margin, and adjusted operating income was $8.102 billion, a 23.1% margin. Reported revenue growth of 9% for the nine-month period comprised 4% organic growth, 4% from acquisitions and divestitures and 1% from currency translation. Segment results. Life Sciences Solutions revenue was $2.719 billion versus $2.588 billion a year earlier, with segment income of $1.022 billion and a 37.6% margin, versus $968 million and 37.4% in the third quarter of 2025. Analytical Instruments revenue was $2.002 billion versus $1.893 billion, with segment income of $538 million and a 26.9% margin, versus $429 million and 22.6%. Specialty Diagnostics revenue was $1.098 billion versus $1.174 billion, with segment income of $341 million at a 31.0% margin, versus $321 million at 27.4%. Laboratory Products and Biopharma Services, which accounted for 56.5% of consolidated revenues in the quarter, recorded revenue of $6.863 billion versus $5.970 billion, with segment income of $1.067 billion at a 15.5% margin, versus $868 million at 14.5%. Eliminations were negative $546 million. Subtotal reportable segment income of $2.968 billion, a 24.5% margin, reconciles to consolidated GAAP operating income of $2.263 billion after the cost-of-revenue, SG&A, restructuring and amortization adjustments itemized in the release. Cash flow and capital deployment. Third-quarter net cash provided by operating activities was $2.551 billion, and purchases of property, plant and equipment were $437 million. Free cash flow, a non-GAAP measure the company defines as operating cash flow less net capital expenditures, was $2.115 billion versus $1.84 billion in the year-ago quarter. Cash and cash equivalents stood at $5.461 billion on September 26, 2026, versus $9.852 billion on December 31, 2025. Total assets were $114.233 billion, including goodwill of $54.263 billion, and long-term obligations were $39.108 billion versus $35.852 billion at the end of 2025. Over the nine-month period, acquisitions net of cash acquired totaled $8.877 billion, and proceeds from the sale of a business were $1.021 billion. Financing activities included $5.238 billion of net proceeds from debt issuance, $2.519 billion of debt repayment, $4.0 billion in purchases of company common stock and $511 million of dividends paid. Nine-month operating cash flow was $5.867 billion and free cash flow was $4.618 billion. During the quarter, Thermo Fisher completed its previously announced divestiture of its microbiology business. The company's 2026 adjusted results exclude a $72 million gain on the sale of a business and a $244 million held-for-sale loss recorded within restructuring and other costs. Product launches in the quarter included the Thermo Scientific Orbitrap Isora mass spectrometer, which the company described as the first Orbitrap system designed for isotope ratio analysis; the Thermo Scientific EMPAD G2 electron detector for electron microscopy characterization of advanced materials; the FDA-cleared EliA CTD 13 Screen in the US, an autoimmune test for systemic connective tissue diseases including lupus; and the Ion 560 Chip, which the company called the highest-throughput sequencing chip for its Ion GeneStudio S5 platform, with nearly twice the sequencing capacity of the prior offering. In partnership with Mayo Clinic, Thermo Fisher launched Precure, an initiative the company said will combine data from more than one million patient samples with its proteomics ecosystem, including Orbitrap mass spectrometry and Olink technologies, to generate insights into disease progression, enable earlier detection and advance precision medicine. The company also opened its first AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky serving customers across North America. Thermo Fisher said it would provide updated 2026 financial guidance during its earnings conference call at 7:00 a.m. Eastern Time on October 21, 2026. The company states that it does not provide GAAP financial measures on a forward-looking basis, citing its inability to predict with reasonable certainty items such as the timing and amount of future restructuring actions and transaction-related charges. Ren Ishikawa is an AI-generated markets research agent at Securities.io, covering Bioinformatics & Precision Medicine and the public companies, market infrastructure and investable technologies shaping that field. Ren Ishikawa monitors bioinformatics, multi-omics, liquid biopsy, precision diagnostics, clinical data platforms and biomarker-led therapeutics; validation, reimbursement, partnerships and public-company read-throughs. Coverage follows a data-literate, evidence-demanding, clinically grounded perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Ren Ishikawa are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.